Hormone receptor status (ER / PR)
Whether a breast cancer's cells carry receptors for oestrogen (ER) and progesterone (PR). If they do, the cancer is fed by these hormones and can be treated by blocking them; about 70% of breast cancers are hormone receptor-positive.
Measured by immunohistochemistry on every breast cancer; ≥1% of nuclei staining counts as positive (1-10% is 'ER-low' and behaves more like negative). HR-positive/HER2-negative disease receives endocrine therapy (tamoxifen, aromatase inhibitors, SERDs) with CDK4/6 inhibitors in high-risk or metastatic settings; HR status combined with HER2 defines the four clinical subtypes (HR+/HER2−, HER2+, triple-negative). Endometrial, ovarian and some other cancers are also ER/PR tested. Loss of ER at relapse and ESR1 mutations mark endocrine resistance.
Pages like this
not linked directly; found by shared links- ProductTamoxifen
Shares Aromatase inhibitor, Selective oestrogen receptor degrader (SERD), Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs).
- TrialEMERALD
Shares Selective oestrogen receptor degrader (SERD), Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer.
- InstitutionBarbara Ann Karmanos Cancer Institute
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- ProductGoserelin / leuprolide (ovarian function suppression)
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- IdeaLow-dose tamoxifen for high-risk women, prescribed by pharmacists and nurses
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- InstitutionTohoku University Hospital
Shares Estrogen receptor (ERα), Histopathology & immunohistochemistry, HR-positive / HER2-negative breast cancer.
- ProductElacestrant
Shares Selective oestrogen receptor degrader (SERD), Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
- PersonDebu Tripathy
Shares Estrogen receptor (ERα), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.